Navamedic ASA is a Nordic pharmaceutical company headquartered in Oslo, Norway, specializing in the supply of high-quality prescription drugs, consumer health products, and medical nutrition to hospitals and pharmacies. Incorporated in 2002 and listed on the Oslo Stock Exchange since 2006, it addresses key public health challenges such as obesity, Parkinson’s disease, antibiotics, addiction treatment, metabolism, cardiology, urology, and women’s health. The company operates across the Nordic countries—Norway, Sweden, Denmark, and Finland—as well as the Benelux region, Baltics, UK, and Greece, with a team of approximately 42 professionals. Navamedic’s portfolio includes Rx and OTC pharmaceuticals, medical devices, food supplements, and cosmetics, sourced via strategic distribution agreements and in-licensing deals. Notable developments include the 2025 acquisition of the dne pharma business to strengthen addiction treatment and innovations in personalized Parkinson’s dosing solutions. Achieving sales of 531 million NOK in 2024, Navamedic serves as a vital partner for international firms seeking market access in Northern Europe through its regulatory expertise and local insights.